Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA
treatment, HBeAg positive CHB patients who achieved HBV DNA<1000copies/ml but HBeAb negative,
will be randomized (1:1) into 2 study arms as follows:
Arm A: Peginterferon alfa-2a 180μg /wk plus NA 1 piece qd for 48 weeks Arm B: Entecavir 0.5mg
qd for 48 weeks